Traditional biomarkers—estrogen receptor (ER), progesterone receptor (PR), and HER2—retain their prognostic and predictive value in multifocal (MF) and multicentric (MC) breast cancers, as they do in unifocal cases. This evidence concerns the gene ESR1 and breast carcinoma.